Charles Schwab Investment Management Inc Biotechnology

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$113B	$756 Million 0.15% of portfolio	1,626,347	Q3 2024 Added 1.27%
REGN Regeneron Pharmaceuticals, Inc.	$72.4B	$708 Million 0.14% of portfolio	673,261	Q3 2024 Added 1.74%
PCVX Vaxcyte, Inc.	$5.32B	$148 Million 0.03% of portfolio	1,295,837	Q3 2024 Added 47.89%
MRNA Moderna, Inc.	$16.2B	$143 Million 0.03% of portfolio	2,132,777	Q3 2024 Added 4.05%
ALNY Alnylam Pharmaceuticals, Inc.	$34.3B	$134 Million 0.03% of portfolio	487,348	Q3 2024 Added 3.56%
UTHR United Therapeutics Corp	$16.9B	$133 Million 0.03% of portfolio	369,955	Q3 2024 Reduced 4.6%
TECH Bio Techne Corp	$3.02B	$113 Million 0.02% of portfolio	1,414,003	Q3 2024 Reduced 5.92%
INCY Incyte Corp	$16.1B	$106 Million 0.02% of portfolio	1,609,220	Q3 2024 Added 29.25%
INSM Insmed Inc	$10.6B	$105 Million 0.02% of portfolio	1,444,266	Q3 2024 Added 10.54%
HALO Halozyme Therapeutics, Inc.	$7.77B	$101 Million 0.02% of portfolio	1,773,397	Q3 2024 Reduced 0.79%
BMRN Biomarin Pharmaceutical Inc	$11.5B	$98.5 Million 0.02% of portfolio	1,401,628	Q3 2024 Added 4.14%
EXEL Exelixis, Inc.	$10.4B	$85 Million 0.02% of portfolio	3,273,620	Q3 2024 Reduced 1.0%
RPRX Royalty Pharma PLC	$13.6B	$84.9 Million 0.02% of portfolio	3,001,603	Q3 2024 Added 58.12%
RVMD Revolution Medicines, Inc.	$3.59B	$79.9 Million 0.02% of portfolio	1,763,117	Q3 2024 Added 58.88%
SRPT Sarepta Therapeutics, Inc.	$10.2B	$76.4 Million 0.01% of portfolio	611,749	Q3 2024 Added 1.16%
CYTK Cytokinetics Inc	$4.78B	$69.8 Million 0.01% of portfolio	1,321,391	Q3 2024 Added 42.75%
JAZZ Jazz Pharmaceuticals PLC	$7.65B	$59.3 Million 0.01% of portfolio	531,710	Q3 2024 Added 8.71%
IONS Ionis Pharmaceuticals Inc	$4.93B	$57.8 Million 0.01% of portfolio	1,443,020	Q3 2024 Added 8.65%
BPMC Blueprint Medicines Corp	$6.86B	$55.2 Million 0.01% of portfolio	597,232	Q3 2024 Added 9.28%
ADMA Adma Biologics, Inc.	$3.16B	$48 Million 0.01% of portfolio	2,401,533	Q3 2024 Added 11.59%
CORT Corcept Therapeutics Inc	$6.43B	$47.5 Million 0.01% of portfolio	1,026,487	Q3 2024 Added 5.47%
RNA Avidity Biosciences, Inc.	$1.55B	$45.5 Million 0.01% of portfolio	990,182	Q3 2024 Added 24.85%
VKTX Viking Therapeutics, Inc.	$2.68B	$45.3 Million 0.01% of portfolio	715,597	Q3 2024 Added 6.57%
KRYS Krystal Biotech, Inc.	$3.97B	$43.7 Million 0.01% of portfolio	240,216	Q3 2024 Added 8.97%
CRSP Crispr Therapeutics Ag	$3.39B	$34 Million 0.01% of portfolio	724,241	Q3 2024 Added 0.92%
CRNX Crinetics Pharmaceuticals, Inc.	$2.09B	$33.5 Million 0.01% of portfolio	655,418	Q3 2024 Added 9.78%
RARE Ultragenyx Pharmaceutical Inc.	$3.09B	$33 Million 0.01% of portfolio	594,521	Q3 2024 Added 10.58%
BBIO Bridge Bio Pharma, Inc.	$5.57B	$32.7 Million 0.01% of portfolio	1,284,802	Q3 2024 Added 8.04%
NUVL Nuvalent, Inc.	$3.53B	$32.3 Million 0.01% of portfolio	315,827	Q3 2024 Added 19.05%
ROIV Roivant Sciences Ltd.	$7.87B	$31.9 Million 0.01% of portfolio	2,767,412	Q3 2024 Added 30.49%
MDGL Madrigal Pharmaceuticals, Inc.	$5.61B	$31.4 Million 0.01% of portfolio	147,970	Q3 2024 Added 6.98%
SMMT Summit Therapeutics Inc.	$4.78B	$31.4 Million 0.01% of portfolio	1,432,713	Q3 2024 Added 53.28%
DNLI Denali Therapeutics Inc.	$2.98B	$29.6 Million 0.01% of portfolio	1,015,810	Q3 2024 Reduced 4.11%
AXSM Axsome Therapeutics, Inc.	$4.42B	$29 Million 0.01% of portfolio	322,596	Q3 2024 Added 4.12%
FOLD Amicus Therapeutics, Inc.	$2.7B	$28.5 Million 0.01% of portfolio	2,667,271	Q3 2024 Added 10.01%
TGTX Tg Therapeutics, Inc.	$4.54B	$27.7 Million 0.01% of portfolio	1,184,609	Q3 2024 Added 0.67%
APLS Apellis Pharmaceuticals, Inc.	$3.3B	$27.6 Million 0.01% of portfolio	956,362	Q3 2024 Added 0.98%
ACLX Arcellx, Inc.	$2.76B	$27.4 Million 0.01% of portfolio	328,093	Q3 2024 Added 4.52%
PTCT Ptc Therapeutics, Inc.	$3.32B	$26.2 Million 0.01% of portfolio	706,730	Q3 2024 Added 7.27%
PTGX Protagonist Therapeutics, Inc	$1.85B	$25.4 Million 0.0% of portfolio	565,503	Q3 2024 Added 7.58%
VCYT Veracyte, Inc.	$3.14B	$25 Million 0.0% of portfolio	735,007	Q3 2024 Reduced 3.55%
NVO Novo Nordisk A S	$199B	$24.4 Million 0.0% of portfolio	204,583	Q3 2024 Added 16.51%
DYN Dyne Therapeutics, Inc.	$710M	$23.3 Million 0.0% of portfolio	648,652	Q3 2024 Added 7.92%
CPRX Catalyst Pharmaceuticals, Inc.	$2.32B	$23.2 Million 0.0% of portfolio	1,167,743	Q3 2024 Added 4.55%
RYTM Rhythm Pharmaceuticals, Inc.	$3.22B	$22.7 Million 0.0% of portfolio	433,866	Q3 2024 Added 1.38%
IDYA Ideaya Biosciences, Inc.	$1.14B	$21.8 Million 0.0% of portfolio	689,073	Q3 2024 Added 12.86%
AGIO Agios Pharmaceuticals, Inc.	$1.89B	$20.7 Million 0.0% of portfolio	465,620	Q3 2024 Added 1.77%
GERN Geron Corp	$1.14B	$20.2 Million 0.0% of portfolio	4,450,382	Q3 2024 Added 2.57%
ACAD Acadia Pharmaceuticals Inc	$3.02B	$19.6 Million 0.0% of portfolio	1,271,135	Q3 2024 Reduced 0.32%
ARWR Arrowhead Pharmaceuticals, Inc.	$2.2B	$19.5 Million 0.0% of portfolio	1,006,935	Q3 2024 Added 1.26%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.